Last reviewed · How we verify
HLD200
HLD200 is a histone deacetylase (HDAC) inhibitor that modulates gene expression by blocking HDAC enzymes.
HLD200 is a histone deacetylase (HDAC) inhibitor that modulates gene expression by blocking HDAC enzymes. Used for Peripheral T-cell lymphoma (PTCL).
At a glance
| Generic name | HLD200 |
|---|---|
| Also known as | methylphenidate hydrochloride (MPH) |
| Sponsor | Ironshore Pharmaceuticals and Development, Inc |
| Drug class | HDAC inhibitor |
| Target | Histone deacetylase (HDAC) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
By inhibiting histone deacetylase activity, HLD200 prevents the removal of acetyl groups from histone proteins, leading to increased histone acetylation and altered chromatin structure. This results in changes to gene expression patterns, particularly affecting genes involved in cell proliferation and differentiation. The drug is being developed for hematologic malignancies where HDAC inhibition has shown therapeutic potential.
Approved indications
- Peripheral T-cell lymphoma (PTCL)
Common side effects
- Thrombocytopenia
- Anemia
- Nausea
- Diarrhea
- Fatigue
Key clinical trials
- Efficacy, Safety & Pharmacokinetic (PK) Study of HLD200 in Children Aged 4-5 Years With ADHD (PHASE3)
- Pharmacokinetics of HLD200 in Children and Adolescents With ADHD (PHASE1, PHASE2)
- A Pivotal Efficacy Trial to Evaluate HLD200 in Children With ADHD in a Classroom Setting (PHASE3)
- A Pivotal Efficacy Trial to Evaluate HLD200 in Children With ADHD in a Naturalistic Setting (PHASE3)
- A Trial Evaluating the Efficacy and Safety of HLD200 in Children With ADHD (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HLD200 CI brief — competitive landscape report
- HLD200 updates RSS · CI watch RSS
- Ironshore Pharmaceuticals and Development, Inc portfolio CI